EKF.L

EKF Diagnostics Holdings Plc
EKF Diagnostics Hldg - Trading Update
29th January 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1313B
EKF Diagnostics Holdings PLC
29 January 2024
 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Trading Update

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, provides an unaudited trading update for the year ended 31 December 2023 ("FY 2023").

 

The Company expects to report full-year revenues and adjusted EBITDA1 in-line with management expectations, reflecting continued steady growth from the Point-of-Care division and β-HB sales. Cash, net of bank borrowings, as at 31 December 2023, was £4.4m.

 

Good progress continues to be made in the Life Sciences division's fermentation capacity expansion. Purchase orders for precision fermentation services using the new facility have been received and the Company continues to onboard a number of customers. The Board anticipates that a steady build-up of revenues generated from the new fermentation capacity through 2024, alongside maintained growth across Point-of-Care and β-HB sales.

 

EKF will announce its FY 2023 results in late March 2024 and provide further insight to expected performance for the current financial year at that time.

 

1Earnings before interest, tax, depreciation and amortisation, excluding exceptional items and share based payments.

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair / Stephen Young, CFO

 Tel: +44 (0)29 2071 0570



Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Oliver Platts




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings 

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

 

·    Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFIDLLITFIS]]>
TwitterFacebookLinkedIn